Immune effector cells pre-infected with oncolytic virus

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10064893
APP PUB NO 20150320800A1
SERIAL NO

14792424

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYOFFICE OF THE GENERAL COUNSEL 3RD FLOOR BLDG 170 MAIN QUAD P O BOX 20386 STANFORD CA 94305-2038

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Contag, Christopher H Stanford, US 35 867
Thorne, Stephen H Pittsburgh, US 15 23

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 4, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 4, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00